Compare CYD & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | ANIP |
|---|---|---|
| Founded | 1951 | 2001 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1998 | 1999 |
| Metric | CYD | ANIP |
|---|---|---|
| Price | $37.32 | $72.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $60.00 | ★ $110.00 |
| AVG Volume (30 Days) | 204.2K | ★ 326.6K |
| Earning Date | 02-24-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $15.11 | $23.05 |
| Revenue Next Year | $8.67 | $14.08 |
| P/E Ratio | $32.71 | ★ $22.30 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $12.66 | $56.71 |
| 52 Week High | $56.55 | $99.50 |
| Indicator | CYD | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 33.90 | 41.52 |
| Support Level | $34.98 | $71.29 |
| Resistance Level | $41.24 | $84.47 |
| Average True Range (ATR) | 1.90 | 2.30 |
| MACD | -0.31 | 0.15 |
| Stochastic Oscillator | 9.23 | 34.97 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.